bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure Legends from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Supplementary Figure Legends
Supplemental Figures 1-8 from Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations
Authors: Alvarez-Calderon Francesca , Gregory Mark A. , Pham-Danis Catherine , DeRyckere Deborah , Stevens Brett M. , Zaberezhnyy Vadym , Hill Amanda A. , Gemta Lelisa , Kumar Amit , Kumar Vijay , Wempe Michael F. , Pollyea Daniel A. , Jordan Craig T. , Serkova Natalie J. , Graham Douglas K. , DeGregori James
Published: April 2023

Supplemental Figures 1-8. Figure 1. Mitochondrial metabolism becomes essential for TKI-treated BCR-ABL+ leukemia cells. Figure 2: Oligomycin-A sensitizes cells to BCR-ABL inhibition. Figure 3. Oligomycin-A sensitizes cells to BCR-ABL inhibition. Figure 4. Oligomycin-A sensitizes acute myeloid leukemia cells to TKI. Figure 5. Low nM concentrations of oligomycin-A do not perturb the TCA cycle. Figure 6. Oligomycin-A disrupts mitochondrial functions in leukemia cells. Figure 7. Low dose oligomycin-A synergizes with TKI to eliminate leukemia in vivo with no significant toxicity. Figure 8. Model for how TKI treatment of leukemias creates an altered metabolic state sensitive to mitochondrial perturbations.
Supplementary Figure 1 from Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors
Authors: Roulstone Victoria , Khan Khurum , Pandha Hardev S. , Rudman Sarah , Coffey Matt , Gill George M. , Melcher Alan A. , Vile Richard , Harrington Kevin J. , de Bono Johann , Spicer James
Published: April 2023

Supplementary Figure 1. Total white blood cell numbers were reduced by higher doses of the cytotoxic CP in later cohorts
Supplementary Figure S5 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung
Authors: Starmans Maud HW. , Pintilie Melania , Chan-Seng-Yue Michelle , Moon Nathalie C. , Haider Syed , Nguyen Francis , Lau Suzanne K. , Liu Ni , Kasprzyk Arek , Wouters Bradly G. , Der Sandy D. , Shepherd Frances A. , Jurisica Igor , Penn Linda Z. , Tsao Ming-Sound , Lambin Philippe , Boutros Paul C.
Published: April 2023

Supplementary Figure S5. Predicted RAS status influences prognostic performance of the 3-gene (A-B) and 6-gene (C-D) signature. Kaplan-Meier survival curves for RASwt (A-C) and RASmt (B-D) patients, stratified according to the 3-gene or 6-gene signature.
Supplementary Figure S4 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung
Authors: Starmans Maud HW. , Pintilie Melania , Chan-Seng-Yue Michelle , Moon Nathalie C. , Haider Syed , Nguyen Francis , Lau Suzanne K. , Liu Ni , Kasprzyk Arek , Wouters Bradly G. , Der Sandy D. , Shepherd Frances A. , Jurisica Igor , Penn Linda Z. , Tsao Ming-Sound , Lambin Philippe , Boutros Paul C.
Published: April 2023

Supplementary Figure S4. Kaplan-Meier survival curve for a cohort of 549 adenocarcinoma patients stratified according to predicted RAS pathway activation status.
Supplementary Tables 1-7 from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Authors: Weller Michael , Tabatabai Ghazaleh , Kästner Bärbel , Felsberg Jörg , Steinbach Joachim P. , Wick Antje , Schnell Oliver , Hau Peter , Herrlinger Ulrich , Sabel Michael C. , Wirsching Hans-Georg , Ketter Ralf , Bähr Oliver , Platten Michael , Tonn Jörg C. , Schlegel Uwe , Marosi Christine , Goldbrunner Roland , Stupp Roger , Homicsko Krisztian , Pichler Josef , Nikkhah Guido , Meixensberger Jürgen , Vajkoczy Peter , Kollias Spyros , Hüsing Johannes , Reifenberger Guido , Wick Wolfgang
Published: April 2023

Supplementary Tables 1-7. Supplementary Table 1. Safety and tolerability. Supplementary Table 2. Outcome by MGMT promoter methylation status and treatment arm. Supplementary Table 3. Outcome by interval from last TMZ administration and MGMT promoter methylation status. Supplementary Table 4. Adherence to Mini Mental Status data collection over the course of the study. Supplementary Table 5. Treatment effect (Arm B versus Arm A) on EORTC-QLQ-C30 and -BN20 scales evaluated at timepoint 90 days Supplementary Table 6. Absolute changes of (0-100) score points of quality of life (as assessed by the EORTC-QLQ-C30 and -BN20 scales) within one treatment cycle of 28 days in Arms A and B, along with local p-values for difference in slopes. Supplementary Table 7. Adherence to EORTC-QLQ-BN20 and -C30 data collection over the course of the study.
supplemental legend from Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
Authors: Curry William T. , Gorrepati Ramana , Piesche Matthias , Sasada Tetsuro , Agarwalla Pankaj , Jones Pamela S. , Gerstner Elizabeth R. , Golby Alexandra J. , Batchelor Tracy T. , Wen Patrick Y. , Mihm Martin C. , Dranoff Glenn
Published: April 2023

supplemental legend
ELISA for angiogenic cytokines from Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
Authors: Curry William T. , Gorrepati Ramana , Piesche Matthias , Sasada Tetsuro , Agarwalla Pankaj , Jones Pamela S. , Gerstner Elizabeth R. , Golby Alexandra J. , Batchelor Tracy T. , Wen Patrick Y. , Mihm Martin C. , Dranoff Glenn
Published: April 2023

Extended methods for ELISA assay for angiogenic cytokines.
Supplemental Material and Methods, Table 1, and Figures 1-7 from Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma
Authors: Gupte Ankita , Baker Emma K. , Wan Soo-San , Stewart Elizabeth , Loh Amos , Shelat Anang A. , Gould Cathryn M. , Chalk Alistair M. , Taylor Scott , Lackovic Kurt , Karlström Åsa , Mutsaers Anthony J. , Desai Jayesh , Madhamshettiwar Piyush B. , Zannettino Andrew C.W. , Burns Chris , Huang David C.S. , Dyer Michael A. , Simpson Kaylene J. , Walkley Carl R.
Published: April 2023

Supplemental Material and Methods, Table 1, and Figures 1-7. Supplemental Table 1 - Primer Sequences used for qPCR. Supplemental Figure 1 - Suppressors of doxorubicin induced cell death from siRNA screen. Supplemental Figure 2 - Response to Spliceostatin A treatment. Supplemental Figure 3 - Dose response of curves of murine and human OS cells to dual PI3K/mTOR inhibitors. Supplemental Figure 4 - siRNA against PI3K subunits and mTOR complex components Supplemental Figure 5 - BYL719 and Everolimus Synergy Matrix Supplemental Figure 6 - BYL719 and Everolimus treatment of primary murine osteoblasts. Supplemental Figure 7. GSK2126458 treatment reduces OS tumour proliferation in vivo.
Supplementary Figures from Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer
Authors: Patel Hetal , Abduljabbar Rezvan , Lai Chun-Fui , Periyasamy Manikandan , Harrod Alison , Gemma Carolina , Steel Jennifer H. , Patel Naina , Busonero Claudia , Jerjees Dena , Remenyi Judit , Smith Sally , Gomm Jennifer J. , Magnani Luca , Győrffy Balázs , Jones Louise J. , Fuller-Pace Frances , Shousha Sami , Buluwela Laki , Rakha Emad A. , Ellis Ian O. , Coombes R. Charles , Ali Simak
Published: April 2023

Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. Supplementary Figure 2. Relationship between mRNA levels of CDK7, cyclin H and MAT1 in breast cancer. Supplementary Figure 3. Profiling of CDK7, Cyclin H and MAT1 expression in the cell cycle. Supplementary Figure 4. Expression of CDK7, CyclinH and MAT1 is elevated in breast cancer. Supplementary Figure 5. CDK7, CyclinH and MAT1 expression is not estrogen regulated in breast cancer cells. Supplementary Figure 6. Serine 118 phosphorylation is associated with better prognosis.
Supplementary table 2 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Authors: Böhm Steffen , Montfort Anne , Pearce Oliver M.T. , Topping Joanne , Chakravarty Probir , Everitt Gemma L.A. , Clear Andrew , McDermott Jackie R. , Ennis Darren , Dowe Thomas , Fitzpatrick Amanda , Brockbank Elly C. , Lawrence Alexandra C. , Jeyarajah Arjun , Faruqi Asma Z. , McNeish Iain A. , Singh Naveena , Lockley Michelle , Balkwill Frances R.
Published: April 2023

PDS cohort
Supplementary Materials and Methods, Supplementary Figures 1-4, Supplementary Table Legends, Supplementary Figure Legends from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Authors: Böhm Steffen , Montfort Anne , Pearce Oliver M.T. , Topping Joanne , Chakravarty Probir , Everitt Gemma L.A. , Clear Andrew , McDermott Jackie R. , Ennis Darren , Dowe Thomas , Fitzpatrick Amanda , Brockbank Elly C. , Lawrence Alexandra C. , Jeyarajah Arjun , Faruqi Asma Z. , McNeish Iain A. , Singh Naveena , Lockley Michelle , Balkwill Frances R.
Published: April 2023

Supplementary Table 1. Baseline characteristics and histopathological data of the patients receiving neoadjuvant chemotherapy (NACT) and analysed in this study; Supplementary Table 2. Baseline characteristics of the cohort of patients undergoing primary debulking surgery (PDS); Supplementary Table 3. Number of samples in each experiment; Supplementary Figure 1. (A) Progression-free survival and (B) Overall survival of the study cohort of fifty-four patients undergoing neoadjuvant chemotherapy; Supplementary Figure 2: Representative IHC pictures showing the densities of CD8+, Foxp3+ and CD45 RO+ cells in matched pre and post treatment samples; Supplementary Figure 3. Tumor:stroma ratio of leukocyte counts pre and post NACT The ratio of tumor and stromal IHC scores of CD8 (A), CD45RO (B) and FOXP3 (C) were calculated and plotted before and after NACT for CRS2 bad responders (right figure panel); Supplementary Figure 4. PD-L1 expression (IHC) on immune cells in fiftytwo matched pre- and post NACT biopsies of 26 patients.
Supplemental Figure S6 from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure S6. TNFα increases cell proliferation and is not cytotoxic to uninfected GB cells.
Supplementary Table S2 from Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Authors: Keck Michaela K. , Zuo Zhixiang , Khattri Arun , Stricker Thomas P. , Brown Christopher D. , Imanguli Matin , Rieke Damian , Endhardt Katharina , Fang Petra , Brägelmann Johannes , DeBoer Rebecca , El-Dinali Mohamed , Aktolga Serdal , Lei Zhengdeng , Tan Patrick , Rozen Steve G. , Salgia Ravi , Weichselbaum Ralph R. , Lingen Mark W. , Story Michael D. , Ang K. Kian , Cohen Ezra E.W. , White Kevin P. , Vokes Everett E. , Seiwert Tanguy Y.
Published: April 2023

Supplementary Table S2. Centroids of the 821 gene signature for the three super-groups
Supplementary Figure S4 from Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Authors: Keck Michaela K. , Zuo Zhixiang , Khattri Arun , Stricker Thomas P. , Brown Christopher D. , Imanguli Matin , Rieke Damian , Endhardt Katharina , Fang Petra , Brägelmann Johannes , DeBoer Rebecca , El-Dinali Mohamed , Aktolga Serdal , Lei Zhengdeng , Tan Patrick , Rozen Steve G. , Salgia Ravi , Weichselbaum Ralph R. , Lingen Mark W. , Story Michael D. , Ang K. Kian , Cohen Ezra E.W. , White Kevin P. , Vokes Everett E. , Seiwert Tanguy Y.
Published: April 2023

Supplementary Figure S4. Keratinization and differentiation in HNSCC subtypes. Samples in mesenchymal HPV subtype do not show keratinization and most of them are poorly differentiated. Conversely, most samples in basal subype are keratinizing and show moderate to well differentiation.
Supplementary Figure S2 from Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Authors: Keck Michaela K. , Zuo Zhixiang , Khattri Arun , Stricker Thomas P. , Brown Christopher D. , Imanguli Matin , Rieke Damian , Endhardt Katharina , Fang Petra , Brägelmann Johannes , DeBoer Rebecca , El-Dinali Mohamed , Aktolga Serdal , Lei Zhengdeng , Tan Patrick , Rozen Steve G. , Salgia Ravi , Weichselbaum Ralph R. , Lingen Mark W. , Story Michael D. , Ang K. Kian , Cohen Ezra E.W. , White Kevin P. , Vokes Everett E. , Seiwert Tanguy Y.
Published: April 2023

Supplementary Figure S2. Workflow of training HNSCC subtypes and consensus clustering of three training datasets. (A) Workflow of the procedure to identify and validate HNSCC subtypes (B) Consensus clustering in three training datasets identifies five HNC subtypes that differ across platforms. Consensus index matrix for k=5, cumulative distribution function (CDF) for k=2 to k=10 and relative change in area under the CDF curve for k=2 to k=10 are shown. From top to bottom are Agilent (n=134), Illumina (n=131), and Affymetrix (n=106) cohorts.
Supplementary Figure S1 from Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Authors: Keck Michaela K. , Zuo Zhixiang , Khattri Arun , Stricker Thomas P. , Brown Christopher D. , Imanguli Matin , Rieke Damian , Endhardt Katharina , Fang Petra , Brägelmann Johannes , DeBoer Rebecca , El-Dinali Mohamed , Aktolga Serdal , Lei Zhengdeng , Tan Patrick , Rozen Steve G. , Salgia Ravi , Weichselbaum Ralph R. , Lingen Mark W. , Story Michael D. , Ang K. Kian , Cohen Ezra E.W. , White Kevin P. , Vokes Everett E. , Seiwert Tanguy Y.
Published: April 2023

Supplementary Figure S1. Flowchart shows how OCT blocks of frozen tissue samples were obtained from the University of Chicago Head and Neck Cancer tissue bank.
Supplementary Materials from Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer
Authors: Farren Matthew R. , Mace Thomas A. , Geyer Susan , Mikhail Sameh , Wu Christina , Ciombor Kristen , Tahiri Sanaa , Ahn Daniel , Noonan Anne M. , Villalona-Calero Miguel , Bekaii-Saab Tanios , Lesinski Gregory B.
Published: April 2023

Table S1. Antibodies used for flow cytometry Table S2. Monte Carlo cross-validation of continuous measure markers. Table S3. Monte Carlo cross-validation of dichotomous measure markers. Table S4. Pancreatic cancer patient circulating immune cell frequencies Figure S1. Overall survival does not predict plasma MCP-1 levels
Supplementary Figures S5-6 from Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Authors: Yang Yijun , Jia Dingwu , Kim Hogyoung , Abd Elmageed Zakaria Y. , Datta Amrita , Davis Rodney , Srivastav Sudesh , Moroz Krzysztof , Crawford Byron E. , Moparty Krishnarao , Thomas Raju , Hudson Robert S. , Ambs Stefan , Abdel-Mageed Asim B.
Published: April 2023

Figure S5. Growth kinetics of hnRNPH1 siRNA-silenced PC-3 cells; Figure S6, Effect of hnRNPH1 overexpression on growth of LNCaP cells in nude mice.
Supplementary Figures 1-4 from XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer
Authors: Ferreiro-Neira Isabel , Torres Nancy E. , Liesenfeld Lukas F. , Chan Carlos H.F. , Penson Tristan , Landesman Yosef , Senapedis William , Shacham Sharon , Hong Theodore S. , Cusack James C.
Published: April 2023

Supplementary Figure 1. Selinexor induces HT29 and LoVo cell apoptosis; Supplementary Figure 2. Combination of radiation and Selinexor reduces tumor cell radiation survival; Supplementary Figure 3. Body weight of female nude mice; Supplementary Figure 4. mRNA Survivin levels in in vivo models of CRC.
Supplementary Figure legends from XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer
Authors: Ferreiro-Neira Isabel , Torres Nancy E. , Liesenfeld Lukas F. , Chan Carlos H.F. , Penson Tristan , Landesman Yosef , Senapedis William , Shacham Sharon , Hong Theodore S. , Cusack James C.
Published: April 2023

Figure legends of supplementary figures 1, 2, 3, 4.
Supplementary Figure 2 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
Authors: Hobor Sebastijan , Van Emburgh Beth O. , Crowley Emily , Misale Sandra , Di Nicolantonio Federica , Bardelli Alberto
Published: April 2023

PDF file - 133K, Measurements of additional receptor ligands from conditioned media.
Supplementary Tables 1-4 from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor
Authors: Wang Kai , Zhang Qin , Li Danan , Ching Keith , Zhang Cathy , Zheng Xianxian , Ozeck Mark , Shi Stephanie , Li Xiaorong , Wang Hui , Rejto Paul , Christensen James , Olson Peter
Published: April 2023

Supplementary Tables 1-4 Supplemental Table 1: Receptor status, mutation, gene expression and copy number data obtained from TCGA Supplemental Table 2: Sequences surrounding the upstream breakpoint used when estimating the support of the mutant and wildtype allele. Supplemental Table 3: Differential expression of Notch pathway genes between Notch altered vs. wildtype tumors Supplemental Table 4: Amino acid sequences downstream of PEST domain alterations in Notch altered samples
Supplemental Materials and Methods from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor
Authors: Wang Kai , Zhang Qin , Li Danan , Ching Keith , Zhang Cathy , Zheng Xianxian , Ozeck Mark , Shi Stephanie , Li Xiaorong , Wang Hui , Rejto Paul , Christensen James , Olson Peter
Published: April 2023

Supplemental Materials and Methods
supplementary table 4 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Authors: de la Rochefordiere Anne , Kamal Maud , Floquet Anne , Thomas Laurence , Petrow Peter , Petit Thierry , Pop Marius , Fabbro Michel , Kerr Christine , Joly Florence , Sevin Emmanuel , Maillard Sophie , Curé Hervé , Weber Béatrice , Brunaud Claire , Minsat Mathieu , Gonzague Laurence , Berton-Rigaud Dominique , Aumont Maud , Gladieff Laurence , Peignaux Karine , Bernard Virginie , Leroy Quentin , Bieche Ivan , Margogne Audrey , Nadan AnaTereza , Fourchotte Virginie , Diallo Alhassane , Asselain Benard , Plancher Corine , Armanet Sébastien , Beuzeboc Philippe , Scholl Suzy M.
Published: April 2023

supplementary table 4. Multivariate analysis for Complete Clinical Response and Figo stage
supplementary table 3 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Authors: de la Rochefordiere Anne , Kamal Maud , Floquet Anne , Thomas Laurence , Petrow Peter , Petit Thierry , Pop Marius , Fabbro Michel , Kerr Christine , Joly Florence , Sevin Emmanuel , Maillard Sophie , Curé Hervé , Weber Béatrice , Brunaud Claire , Minsat Mathieu , Gonzague Laurence , Berton-Rigaud Dominique , Aumont Maud , Gladieff Laurence , Peignaux Karine , Bernard Virginie , Leroy Quentin , Bieche Ivan , Margogne Audrey , Nadan AnaTereza , Fourchotte Virginie , Diallo Alhassane , Asselain Benard , Plancher Corine , Armanet Sébastien , Beuzeboc Philippe , Scholl Suzy M.
Published: April 2023

supplementary table 3. Response evaluation at 2 time points
Supplementary Figure S6 from HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Authors: Carson Robbie , Celtikci Basak , Fenning Cathy , Javadi Arman , Crawford Nyree , Perez-Carbonell Lucia , Lawler Mark , Longley Daniel B. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Figure S6. STAT3 regulates MEK inhibitor-induced cFLIPL expression.
supplementary table 1 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Authors: de la Rochefordiere Anne , Kamal Maud , Floquet Anne , Thomas Laurence , Petrow Peter , Petit Thierry , Pop Marius , Fabbro Michel , Kerr Christine , Joly Florence , Sevin Emmanuel , Maillard Sophie , Curé Hervé , Weber Béatrice , Brunaud Claire , Minsat Mathieu , Gonzague Laurence , Berton-Rigaud Dominique , Aumont Maud , Gladieff Laurence , Peignaux Karine , Bernard Virginie , Leroy Quentin , Bieche Ivan , Margogne Audrey , Nadan AnaTereza , Fourchotte Virginie , Diallo Alhassane , Asselain Benard , Plancher Corine , Armanet Sébastien , Beuzeboc Philippe , Scholl Suzy M.
Published: April 2023

supplementary table 1. Radiotherapy and Chemotherapy Treatment dose and Surgery
supplementary methods from Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care
Authors: El Messaoudi Safia , Mouliere Florent , Du Manoir Stanislas , Bascoul-Mollevi Caroline , Gillet Brigitte , Nouaille Michelle , Fiess Catherine , Crapez Evelyne , Bibeau Frederic , Theillet Charles , Mazard Thibault , Pezet Denis , Mathonnet Muriel , Ychou Marc , Thierry Alain R.
Published: April 2023

assay description of the Intplex method
Supplementary information from Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care
Authors: El Messaoudi Safia , Mouliere Florent , Du Manoir Stanislas , Bascoul-Mollevi Caroline , Gillet Brigitte , Nouaille Michelle , Fiess Catherine , Crapez Evelyne , Bibeau Frederic , Theillet Charles , Mazard Thibault , Pezet Denis , Mathonnet Muriel , Ychou Marc , Thierry Alain R.
Published: April 2023

Relation of ccfDNA parameters and CEA values with tumor burden
Supplementary Tables and Supplementary Figure Legend from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Ma Cynthia X. , Luo Jingqin , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Griffith Malachi , Griffith Obi L. , Skidmore Zachary L. , Spies Nicholas C. , Ramu Avinash , Trani Lee , Pluard Timothy , Nagaraj Gayathri , Thomas Shana , Guo Zhanfang , Hoog Jeremy , Han Jing , Mardis Elaine , Lockhart Craig , Ellis Matthew J.
Published: April 2023

Supplementary Table S1. Adverse events that led to dose interruption or reduction Supplementary Table S2. Treatment-related Psychiatric Adverse Events (AEs) Supplementary Table S4. PgR Status of the Primary versus Metastatic (Recurrent) Disease of the 29 Evaluable Patients
Lymphocyte gating strategy. from Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Authors: Kim Jennifer E. , Patel Mira A. , Mangraviti Antonella , Kim Eileen S. , Theodros Debebe , Velarde Esteban , Liu Ann , Sankey Eric W. , Tam Ada , Xu Haiying , Mathios Dimitrios , Jackson Christopher M. , Harris-Bookman Sarah , Garzon-Muvdi Tomas , Sheu Mary , Martin Allison M. , Tyler Betty M. , Tran Phuoc T. , Ye Xiaobu , Olivi Alessandro , Taube Janis M. , Burger Peter C. , Drake Charles G. , Brem Henry , Pardoll Drew M. , Lim Michael
Published: April 2023

Cells were first gated on size and singularity by forward scatter and side scatter. Nonviable cells were excluded by live/dead gating. CD3+ live cells were gated on CD4 and CD8. CD3+FoxP3+CD4+ cells were designated as Tregs. TIM-3 vs. PD-1 expression was assessed for each lymphocyte population.
Supplementary Figure S3 from CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells
Authors: Bruns Heiko , Bessell Catherine , Varela Juan Carlos , Haupt Carl , Fang Jerry , Pasemann Shirin , Mackensen Andreas , Oelke Mathias , Schneck Jonathan P. , Schütz Christian
Published: April 2023

Supplementary Figure S3. Schematics of the in vivo experiments performed and in vitro aAPC/aAPCCD47+ proliferation assay.
Supplementary Table S1 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer
Authors: Gilani Rabia A. , Phadke Sameer , Bao Li Wei , Lachacz Eric J. , Dziubinski Michele L. , Brandvold Kristoffer R. , Steffey Michael E. , Kwarcinski Frank E. , Graveel Carrie R. , Kidwell Kelley M. , Merajver Sofia D. , Soellner Matthew B.
Published: April 2023

Kinome-wide profiling data of UM-164 and dasatinib in MDA-MB 231 lysate
Supplementary Figures S1-S12 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer
Authors: Gilani Rabia A. , Phadke Sameer , Bao Li Wei , Lachacz Eric J. , Dziubinski Michele L. , Brandvold Kristoffer R. , Steffey Michael E. , Kwarcinski Frank E. , Graveel Carrie R. , Kidwell Kelley M. , Merajver Sofia D. , Soellner Matthew B.
Published: April 2023

Supplementary Figure S1. Biochemical data for UM-164 and dasatinib. Supplementary Figure S2. Western blots showing the expression of P-Src, P-EGFR and P-p38MAPK in selected TNBC cell lines. Supplementary Figure S3. UM-164 is a dual c-Src/p38 kinase inhibitor in TNBC cell lysate. Supplementary Figure S4. Signaling pathway analysis of SUM 149 cells when treated with dasatinib or UM-164 at their IC50 values (630 nM and 230 nM, respectively). Supplementary Figure S5. Effect on cell invasion of dasatinib alone and dasatinib plus a p38MAPK inhibitor, BIRB-796. Supplementary Figure S6. Effect of dasatinib alone or in combination with p38MAPK inhibitors on the level of P-EGFR/Tyr1068 and P-p38MAPK. Supplementary Figure S7. UM-164 is cytostatic and does not induce apoptosis. Supplementary Figure S8. Histopathology of major organ systems from mice treated with 140 mg/kg UM-164 for 5 days and necropsied. Supplementary Figure S9. In vivo efficacy of UM-164 compared to dasatinib in MDA-MB 231 xenografts. Supplementary Figure S10. Inhibition of p-Src in MDA-MB 468 cells by UM-164 and dasatinib. Supplementary Figure S11. Effect of UM-164, dasatinib alone and in combination with BIRB-796 in spheroid culture. Supplementary Figure S12. Wetsern blot from the UM-164 treated tumor tissues showing expression of P-38MAPK, P-EGFR and P-Src.
Supplementary Data S2 from Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Authors: Sachs Jeffrey R. , Mayawala Kapil , Gadamsetty Satvik , Kang Soonmo Peter , de Alwis Dinesh P.
Published: April 2023

Additional details and examples referred to in article
Supplementary Tables S1-S6, Figures S1-S2 from A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Authors: Bedard Philippe L. , Tabernero Josep , Janku Filip , Wainberg Zev A. , Paz-Ares Luis , Vansteenkiste Johan , Van Cutsem Eric , Pérez-García José , Stathis Anastasios , Britten Carolyn D. , Le Ngocdiep , Carter Kirsten , Demanse David , Csonka Denes , Peters Malte , Zubel Angela , Nauwelaerts Heidi , Sessa Cristiana
Published: April 2023

Supplementary Tables S1-S6, Figures S1-S2. Table S1. Criteria for defining dose-limiting toxicities Table S2. Summary of primary plasma PK parameters for BKM120 by treatment Table S3. Summary of primary plasma PK parameters for GSK1120212 by treatment Table S4. All causality AEs occurring in >10% of patients (all Grades and Grades 3-4; overall and by dose level - escalation and expansion) Table S5. SAEs suspected to be related to treatment (all Grades and Grades 3-4; overall and by dose level) Table S6. Summary statistics of exposure of study drug in the first four cycles and overall by treatment Full analysis set Figure S1A. Percentage change from baseline on p-S6 (H-score) in fresh tumour as per central review by primary site of cancer and treatment - phosphoserine 240-S6 ribosomal protein Figure S1B. Percentage change from baseline on p-S6 (H-score) in fresh tumour as per central review by primary site of cancer and treatment - phosphorylated ribosomal protein S6 235 Figure S1C. Percentage change from baseline on p-ERK (H-score) in fresh tumour as per central review by primary site of cancer and treatment Figure S2. Exposure plot (patients treated at MTD and RP2D, all cycles) Full analysis set Figure S3. Exposure plot (patients treated at MTD and RP2D, first 9 cycles) Full analysis set
Supplementary Figure S2 from A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Authors: Drilon Alexander , Somwar Romel , Wagner Jacob P. , Vellore Nadeem A. , Eide Christopher A. , Zabriskie Matthew S. , Arcila Maria E. , Hechtman Jaclyn F. , Wang Lu , Smith Roger S. , Kris Mark G. , Riely Gregory J. , Druker Brian J. , O'Hare Thomas , Ladanyi Marc , Davare Monika A.
Published: April 2023

The ROS1D2033N mutant retains transforming capacity but is resistant to crizotinib. A. IL-3 withdrawal assay for Ba/F3 cells retrovirally transduced with native CD74-ROS1 or CD74-ROS1D2033N. Total viable cell number was determined by counting cells on days 2, 4, and 6 after removal of IL-3 from the culture medium. B. Apoptosis induction in Ba/F3 CD74-ROS1 and CD74-ROS1D2033N cells after 72 h of inhibitor treatment at the indicated concentrations. Percentage of cells that were Annexin V-positive after inhibitor treatment is indicated as % Apoptotic. 2,000 cells were counted per condition.
Supplementary Table 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

Schematic representation of the TRAIL promoter, its analyzed regions and the occupancy of epi-marks analyzed under indicated conditions.
Supplemental Figure 1 from iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity
Authors: Jayaraman Padmini , Alfarano Matthew G. , Svider Peter F. , Parikh Falguni , Lu Geming , Kidwai Sarah , Xiong Huabao , Sikora Andrew G.
Published: April 2023

Supplemental Figure 1. Tumor-free WT or iNOS KO C57/BL6 mice were treated with L-NIL in drinking water or plain drinking water control for 7 days. Spenocytes were harvested and intracellular staining performed to determine FOXP3+ expression in CD4+ cells and analyzed by FACS. S1i) representative FACS plots of CD4+FOXP3+ T-reg from WT (untreated control and L-NIL groups) and iNOS KO (untreated) mice. S1ii) graphical representation of aggregated data from two independent experiments.
Supplementary Figure 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

The down-regulation of c-Myc by SAHA.
Supplementary Figure 6 from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

Supplementary Figure 6. A, Comparison of serum visfatin levels according to molecular subtypes of breast cancer patients.
Supplemental Tables from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

Supplementary Table 1. Association between clinicopathological characteristics of breast cancer patients and disease-free survival Supplementary Table 2. Association of serum visfatin with disease recurrence after radiotherapy, chemotherapy, or hormone therapy in breast cancer patients
Primer Sequences from Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Authors: Liu Geoffrey , Tu Dongsheng , Lewis Marcia , Cheng Dangxiao , Sullivan Leslie A. , Chen Zhuo , Morgen Eric , Simes John , Price Timothy J. , Tebbutt Niall C. , Shapiro Jeremy D. , Jeffery G. Mark , Mellor J. Daniel , Mikeska Thomas , Virk Shakeel , Shepherd Lois E. , Jonker Derek J. , O'Callaghan Christopher J. , Zalcberg John R. , Karapetis Christos S. , Dobrovic Alexander
Published: April 2023

Supplementary Table 1 Sequencing Primers used for FcGR 2a ( H/R,rs1801274) and FcGR3a (F/V;rs396991) polymorphisms genotyping
Supplemental figures 1-5 from Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation
Authors: Wang Yifan , Liu Hui , Diao Lixia , Potter Adam , Zhang Jianhu , Qiao Yawei , Wang Jing , Proia David A. , Tailor Ramesh , Komaki Ritsuko , Lin Steven H.
Published: April 2023

Supplemental Figure 1. RPPA heat map of H460 cells treated with varying doses of radiation and ganetespib. Supplemental Figure 2. RPPA heat map of A549 cells treated with varying doses of radiation and ganetespib. Supplemental Figure 3. Western blot validation of some of the altered proteins seen on RPPA analysis in H460 cells. Supplemental Figure 4. The apoptosis indicated by Caspase cleavage in RPPA and western blot were confirmed by flow cytometry Annexin V analysis. Supplemental Figure 5. H460 xenograft recapitulated in vitro DNA damage and apoptosis results.
Supplemental Table 1 from Genetic Modulation of Neurocognitive Function in Glioma Patients
Authors: Liu Yanhong , Zhou Renke , Sulman Erik P. , Scheurer Michael E. , Boehling Nicholas , Armstrong Georgina N. , Tsavachidis Spiridon , Liang Fu-Wen , Etzel Carol J. , Conrad Charles A. , Gilbert Mark R. , Armstrong Terri S. , Bondy Melissa L. , Wefel Jeffrey S.
Published: April 2023

Demographic and Clinical Characteristics of Glioma Patients in the Parent Epidemiological Study (N=1247).
Table S4 from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

Table S4. Baseline Values in the Plasma SPARC-Evaluable Population
Figure S2 from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

Figure S2. Correlation of Baseline Plasma SPARC with Stromal SPARC. In total, 218 of 256 in the SPARC IHC evaluable group had baseline plasma values. No correlation was observed between baseline plasma SPARC and stromal SPARC.
Supplementary Table 1 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Table 1. List of oligonucleotides used for semi-quantitative RT-PCR and quanti-tative real-time PCR.
Supplementary Figure and Table Legends from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Figure and Table Legends
Supplementary Tables 1-3 from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang G. , Kothari Vishal , Santola Alyssa , Liu Meilan , Wilder-Romans Kari , Evans Joseph , Batra Nidhi , Bartelink Harry , Hayes Daniel F. , Lawrence Theodore S. , Brown Powel H. , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Sup. Table 1 depicts the synergism between MELK KD and RT in animal models, Sup. Table 2 shows the patient characteristics from the Wang dataset, Sup. Table 3 shows the patient characteristics from the Servant dataset
Supplementary Materials and Methods from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang G. , Kothari Vishal , Santola Alyssa , Liu Meilan , Wilder-Romans Kari , Evans Joseph , Batra Nidhi , Bartelink Harry , Hayes Daniel F. , Lawrence Theodore S. , Brown Powel H. , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Complete details on cell culture, qRT-PCR, si- and shRNA, clonogenic survival, xenograft, flow cytometry, microarray, and statistical experiments and analyses
Sup. Fig. 6-8 from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang G. , Kothari Vishal , Santola Alyssa , Liu Meilan , Wilder-Romans Kari , Evans Joseph , Batra Nidhi , Bartelink Harry , Hayes Daniel F. , Lawrence Theodore S. , Brown Powel H. , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Sup. Fig. 6 depicts proliferation with MELK pertubation, Sup. Fig. 7 depicts apoptosis by cleaved PARP, Sup. Fig. 8 depicts apoptosis by flow cytometry
Supplemental Data from Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Authors: Dolly Saoirse O. , Wagner Andrew J. , Bendell Johanna C. , Kindler Hedy L. , Krug Lee M. , Seiwert Tanguy Y. , Zauderer Marjorie G. , Lolkema Martijn P. , Apt Doris , Yeh Ru-Fang , Fredrickson Jill O. , Spoerke Jill M. , Koeppen Hartmut , Ware Joseph A. , Lauchle Jennifer O. , Burris Howard A. , de Bono Johann S.
Published: April 2023

Supplementary Table 1. Dose reductions and discontinuations in stage 2 Supplementary Table 2. Pharmacokinetic parameters of apitolisib Supplementary Table 3. Summary of radiological responses at the recommended phase 2 doses of 40mg and 30mg 28/28 day schedule for solid tumors and malignant pleural mesothelioma (MPM) patients, respectively. Supplementary Table 4. Characteristics of pleural mesothelioma patients treated with apitolisib Supplementary Figure 1: Apitolisib study schematic Supplementary Figure 2 (A) Waterfall of FDG-PET responses to apitolisib for subjects with higher (black bars) or lower (grey bars) steady-state AUC0-24h than the median exposure for the RP2D of 40 mg QD. (B) The corresponding change in pre-scan fasting blood glucose (FBG) for each patient relative to baseline values during PET procedure. Supplementary Figure 3 CT thorax and MRI pelvis images demonstrate confirmed partial response in E545K PIK3CA mutant clear cell ovarian carcinoma with lung and right common iliac lymphadenopathy on third line apitolisib.
Supplementary Table S1 from Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Authors: Brown Jennifer R. , Davids Matthew S. , Rodon Jordi , Abrisqueta Pau , Kasar Siddha N. , Lager Joanne , Jiang Jason , Egile Coumaran , Awan Farrukh T.
Published: April 2023

Table S1. Molecular profiling in eleven patients with CLL or lymphoma treated with pilaralisib (SAR245408). For CLL samples, mutation analysis was performed by whole exome sequencing on the Genomics Platform at the Broad Institute. For lymphoma samples, mutation analysis was performed on the FoundationOne NGS platform (T5 gene array) at Foundation Medicine. Patient numbers (column 2) refer to Figure 3.
Supplementary Figure 4 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Authors: Kakavand Hojabr , Wilmott James S. , Menzies Alexander M. , Vilain Ricardo , Haydu Lauren E. , Yearley Jennifer H. , Thompson John F. , Kefford Richard F. , Hersey Peter , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Figure 4. Decision tree used to categorize the pattern of PD-L1 positive staining based on the immune cell infiltrate, percentage of tumor cells expressing PD-L1 and the location of staining within the samples.
Supplementary Table 4 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

Combination of multiple biomarkers in the discrimination of MM patients from patients with effusions due to other cause
Supplementary Figure 3 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Authors: Kakavand Hojabr , Wilmott James S. , Menzies Alexander M. , Vilain Ricardo , Haydu Lauren E. , Yearley Jennifer H. , Thompson John F. , Kefford Richard F. , Hersey Peter , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Figure 3. Kaplan-Meier plots for progression-free survival (PFS) and overall survival (OS).
Supplementary Table 2 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

Univariate analysis
Supplementary Figure 1 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Authors: Kakavand Hojabr , Wilmott James S. , Menzies Alexander M. , Vilain Ricardo , Haydu Lauren E. , Yearley Jennifer H. , Thompson John F. , Kefford Richard F. , Hersey Peter , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Figure 1. Heat map of patients grouped based on baseline (PRE) PD-L1, change in (Î”) PD-L1 expression, Î” tumor infiltrating lymphocytes (TILs) and Î” PD-1+ lymphocytes from PRE to early during treatment (EDT).
Supplementary Figure 2 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

Relative percentages of different HMGB1 isoforms
Supplementary Table S2 from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Authors: Tateishi Kensuke , Iafrate A. John , Ho Quan , Curry William T. , Batchelor Tracy T. , Flaherty Keith T. , Onozato Maristela L. , Lelic Nina , Sundaram Sudhandra , Cahill Daniel P. , Chi Andrew S. , Wakimoto Hiroaki
Published: April 2023

Supplementary Table 2. Relationship of NAMPT inhibitor sensitivity, MYC/MYCN amplification, and Myc/N-Myc protein expression status in glioblastoma tumorsphere lines
Supplementary methods and figures S1-S8 from Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate
Authors: Korangath Preethi , Teo Wei Wen , Sadik Helen , Han Liangfeng , Mori Noriko , Huijts Charlotte M. , Wildes Flonne , Bharti Santosh , Zhang Zhe , Santa-Maria Cesar A. , Tsai Hualing , Dang Chi V. , Stearns Vered , Bhujwalla Zaver M. , Sukumar Saraswati
Published: April 2023

Supplementary methods and figures S1-S8. (S1): Glutamine dependency and induction of apoptosis on glutamine withdrawal in breast cancer cells. (S2): Cytotoxicity of AOA in breast cancer cells. (S3): Myc regulation of transaminases and glutamine dependency in mouse tumor cell lines. (S4): NMR spectra of AOA-treated compared to vehicle-treated SUM159 cells. (S5): Cell cycle arrest and BrdU incorporation after AOA treatment in SUM149 cells; irreversible growth arrest by AOA in SUM149 and 159 cells; partial rescue of cell death due to glutamine withdrawal by exogenous aspartate in breast cancer cell lines. (S6): Western blot analysis showing change in ER stress markers, energy metabolism and apoptosis by AOA treatment in SUM149, SUM159 and MDA-MB-231 cells. (S7): Tumor growth inhibition by AOA in MCF-7, SUM149 and SUM159 xenografts; immunohistochemistry analysis of cleaved caspase 3 in AOA treated tumors; quantitation of ER stress markers in AOA treated tumors. (S8): Effect of AOA in combination with paclitaxel or carboplatin in SUM149 and SUM159 xenografts; up regulation of c-myc in carboplatin and paclitaxel treated MDA-MB-231 xenografts.
Supplementary table 1 from Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer
Authors: Banerjee Sulagna , Modi Shrey , McGinn Olivia , Zhao Xianda , Dudeja Vikas , Ramakrishnan Sundaram , Saluja Ashok K.
Published: April 2023

Genes upregulated in KPC tumors vs mouse PDC
Supplemental Table 2 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
Authors: Boyiadzis Michael , Arora Mukta , Klein John P. , Hassebroek Anna , Hemmer Michael , Urbano-Ispizua Alvaro , Antin Joseph H. , Bolwell Brian J. , Cahn Jean-Yves Y. , Cairo Mitchell S. , Cutler Corey S. , Flowers Mary E. , Gale Robert P. , Herzig Roger , Isola Luis M. , Jacobsohn David A. , Jagasia Madan H. , Klumpp Thomas R. , Lee Stephanie J. , Petersdorf Effie W. , Santarone Stella , Spellman Stephen R. , Schouten Harry C. , Verdonck Leo F. , Wingard John R. , Weisdorf Daniel J. , Horowitz Mary M. , Pavletic Steven Z.
Published: April 2023

Supplemental Table 2. Multivariate analysis showing impact of cGVHD characteristics in CML patients on relapse